Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gogoro Inc (GGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gogoro Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Gogoro Inc trades at $3.9 (market cap $76.99M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 58.3× Gogoro Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | GGR | |
|---|---|---|
Market Cap | $4.49B | $76.99M |
Sector | Health | Technology |
52-Week High | $28.06 | $7.89 |
52-Week Low | $20.06 | $2.74 |
Enterprise Value | $3.69B | $379.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GGR trades at $3.94, down 0.51% today, with a bearish technical signal and negative profitability. The company reported a net loss of $79.97 million on $281.48 million revenue for 2025, though operating cash flow improved to $35.90 million. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvements and growth initiatives.
The outlook remains challenging due to persistent losses and negative ROE, but low valuation multiples and projected cash flow improvements offer potential upside if execution improves. Key risks include sustained unprofitability and competitive pressures in the mobility sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
